Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis

Therapeutic options with immunosuppressive agents for glomerular diseases have widened with refinements to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines from 2012 to 2021. However, international guidelines do not necessarily match the reality in each country. Expensive therapies su...

Descripción completa

Detalles Bibliográficos
Autor principal: Nagai, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054564/
https://www.ncbi.nlm.nih.gov/pubmed/36984602
http://dx.doi.org/10.3390/medicina59030601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054564/
https://www.ncbi.nlm.nih.gov/pubmed/36984602
http://dx.doi.org/10.3390/medicina59030601

Ejemplares similares